The European Society of Medicine’s journal Medical Research Archives has published a peer-reviewed article detailing GeoVax Labs’ next-generation COVID-19 vaccine candidate, GEO-CM04S1, specifically designed for immunocompromised patients. The article, ‘GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients,’ provides scientific rationale and clinical data supporting this vaccine’s development to address limitations of first-generation COVID-19 vaccines in vulnerable populations.
GEO-CM04S1 employs a dual-antigen design expressing both spike and nucleocapsid proteins of SARS-CoV-2 delivered via a Modified Vaccinia Ankara viral vector. This approach aims to generate broad and durable antibody and T-cell responses, targeting conserved viral components less susceptible to mutation. The publication emphasizes how next-generation vaccines stimulating robust cellular immunity may offer improved protection for high-risk groups who often respond inadequately to spike-protein-focused vaccines.
Key findings from the publication include the vaccine’s ability to induce strong CD4+ and CD8+ T-cell responses critical for controlling viral infection and reducing severe disease progression. Early clinical studies demonstrated favorable safety profiles and strong immunologic responses across multiple dose levels, including seroconversion and cellular immune activation. Encouraging results from ongoing Phase 2 trials in patients with hematologic malignancies receiving cell transplants and individuals with chronic lymphocytic leukemia indicate the vaccine can generate durable immune responses even in those with impaired immune systems.
David Dodd, Chairman and CEO of GeoVax, stated that this publication reinforces the scientific rationale for GEO-CM04S1 as a purpose-built vaccine for immunocompromised populations. He noted that approximately 40 million patients in the U.S. and an estimated 400 million worldwide have weakened immune systems, placing them at higher risk of severe COVID-19 outcomes despite vaccination. These populations include cancer patients, transplant recipients, individuals receiving immunosuppressive therapies, and those with chronic diseases.
Mark J. Newman, PhD, Chief Scientific Officer of GeoVax and co-author, explained that GEO-CM04S1 was specifically designed to stimulate strong T-cell responses, which play a critical role in controlling SARS-CoV-2 infection and preventing severe disease. The MVA vector platform provides an ideal backbone for next-generation vaccines due to its ability to safely induce durable humoral and cellular immunity. Data from small animal studies indicates efficacy against variants is induced, potentially reducing the need for continual vaccine updates. For more information about GeoVax’s broader pipeline, visit https://www.geovax.com.
The vaccine is currently being evaluated in multiple Phase 2 clinical trials as both primary vaccination in immunocompromised individuals and as booster vaccination in patients with chronic lymphocytic leukemia. Its multi-antigen design and viral vector platform are intended to provide broader, more durable immune protection in populations where first-generation vaccines have demonstrated reduced effectiveness, addressing a significant unmet medical need in global pandemic preparedness.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax’s Next-Generation COVID-19 Vaccine Shows Promise for Immunocompromised Patients.